RayKnowChina Research Map
Shortlist0

HefeiAnhui Medical University

Second Affiliated Hospital of Anhui Medical University

安徽医科大学第二附属医院

Listed for 17 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Second Affiliated Hospital of Anhui Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌1 paper led
  2. Hepatocellular carcinoma肝细胞癌27 papers led
  3. Stomach cancer胃癌21 papers led
  4. Retinoblastoma视网膜母细胞瘤1 paper led
  5. Osteosarcoma骨肉瘤6 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  7. Neuroblastoma神经母细胞瘤2 papers led
  8. Ewing sarcoma尤文肉瘤1 paper led
  9. Multiple myeloma多发性骨髓瘤7 papers led
  10. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病4 papers led
  11. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症1 paper led
  12. Haemophilia A血友病 A4 papers led
  13. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  14. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病2 papers led
  15. Idiopathic pulmonary fibrosis特发性肺纤维化4 papers led
  16. IgA nephropathyIgA 肾病0 papers led
  17. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led

Not listed for: Nasopharyngeal carcinoma, Hepatoblastoma, Chordoma, Aplastic anaemia, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Fanconi anaemia, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 1 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.03%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

4 hospitals in Hefei for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06644781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou

  2. Recruiting
    Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Registry
    NCT06780111

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Hefei, Nanchang, Xiamen, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncology
Papers it led1
  1. Brain metastasis from esophageal squamous cell carcinoma: a clinical review of 30 cases.2023Neoplasma
All its trials on ClinicalTrials.gov, any status10
  1. Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)RecruitingNCT06780111Study sitePhase 1/Phase 2Start 2025-07
  2. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  3. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  4. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  5. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).TerminatedNCT04949256Study sitePhase 3Start 2021-07
  6. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid TumorsStatus unknownNCT05602792Study sitePhase 1/Phase 2Start 2020-04
  7. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10
  8. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  9. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Study sitePhase 3Start 2018-01
  10. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
More papers found outside PubMed (not counted)10
  1. 2125P A phase II study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  2. 187P Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: An individual patient data (IPD) pooled analysis of 987 patients from three prospective observational cohort studies2024Annals of Oncologyarticle
  3. Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC).2024Journal of Clinical Oncologyconference-abstract
  4. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncologyconference-abstract
  5. 1020MO AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell 2023Annals of Oncologyarticle
  6. O-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)2023Annals of Oncologyarticle
  7. 155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm pha2021Annals of Oncologyarticle
  8. CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncologyconference-abstract
  9. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncologyconference-abstract
  10. RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 27 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
27
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 6620212022: 4420222023: 4420232024: 5520242025: 772025

3 hospitals in Hefei for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging, AI & early detectionRecurrence & prognosisImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyRadiology / nuclear medicineGastroenterology / hepatology
Papers it led27
  1. Integrative metabolomic and transcriptomic profiling reveals distinct metabolic signatures of hepatocellular carcinoma arising from cirrhosis.2026Computational biology and chemistry
  2. An elevated percentage of CD4⁺CD25⁺CD127low regulatory T cells in peripheral blood indicates a poorer prognosis in hepatocellular carcinoma after curative hepatectomy.2025BMC gastroenterologyFree full text
  3. circCCNY enhances lenvatinib sensitivity and suppresses immune evasion in hepatocellular carcinoma by serving as a scaffold for SMURF1 mediated HSP60 degradation.2025Cancer letters
  4. Chemokines and PI3K/AKT signaling pathway mediate the spontaneously ruptured hepatocellular carcinoma through the regulation of the cell cycle.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  5. Assessing the effectiveness of camrelizumab plus anti-angiogenesis drug for the treatment of advanced liver cancer: a single‑center retrospective study.2025Immunopharmacology and immunotoxicology
  6. Pyrazolamide derivative T1 inhibits hepatocellular carcinoma cell proliferation through MAPK pathway modulation.2025International immunopharmacology
  7. Development of a Better Nomogram for Prediction of Preoperative Microvascular Invasion and Postoperative Prognosis in Hepatocellular Carcinoma Patients: A Comparison Study.2025Journal of computer assisted tomographyFree full text
  8. Development and validation of a nomogram model for predicting acute hepatic dysfunction post-intervention in primary hepatocellular carcinoma: a retrospective case-control study.2025World journal of surgical oncologyFree full text
  9. Poly(lactic acid hydroxyacetic acid)-poly(ethylene glycol)-modified ginsenoside Rg3 nanomedicine enhances anti-tumor effect in hepatocellular carcinoma.2024Drug development and industrial pharmacy
  10. CDKL3 is a promising biomarker for diagnosis and prognosis prediction in patients with hepatocellular carcinoma.2024Experimental biology and medicine (Maywood, N.J.)Free full text
  11. TuBG1 promotes hepatocellular carcinoma via ATR/P53-apoptosis and cycling pathways.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  12. Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies.2024Targeted oncology
  13. Dual-energy computed tomography iodine quantification combined with laboratory data for predicting microvascular invasion in hepatocellular carcinoma: a two-centre study.2024The British journal of radiologyFree full text
  14. A comprehensive computational analysis to explore the importance of SIGLECs in HCC biology.2023BMC gastroenterologyFree full text
  15. Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study.2023Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  16. Incidence and predictors of abdominal pain after transarterial chemoembolization of hepatocellular carcinoma: a single-center retrospective study.2023European journal of oncology nursing : the official journal of European Oncology Nursing Society
  17. Hepatocellular carcinoma-derived FOXO1 inhibits tumor progression by suppressing IL-6 secretion from macrophages.2023Neoplasia (New York, N.Y.)Free full text
  18. Prognostic factors in hepatocellular carcinoma patients with Child-Pugh A liver function after hepatectomy: Not related to the surgical approach.2022Annals of hepatology
  19. Comprehensive Analysis of Aldehyde Dehydrogenases (ALDHs) and Its Significant Role in Hepatocellular Carcinoma.2022Biochemical geneticsFree full text
  20. Astragaloside IV suppresses migration and invasion of TGF-β1-induced human hepatoma HuH-7 cells by regulating Nrf2/HO-1 and TGF-β1/Smad3 pathways.2022Naunyn-Schmiedeberg's archives of pharmacology
  21. Artificial intelligence in liver ultrasound.2022World journal of gastroenterologyFree full text
  22. The role of miRNA125b in the progression of hepatocellular carcinoma.2021Clinics and research in hepatology and gastroenterology
  23. Phospho-Smad3L promotes progression of hepatocellular carcinoma through decreasing miR-140-5p level and stimulating epithelial-mesenchymal transition.2021Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  24. Do combined assays of serum AFP, AFP-L3, DCP, GP73, and DKK-1 efficiently improve the clinical values of biomarkers in decision-making for hepatocellular carcinoma? A meta-analysis.2021Expert review of gastroenterology & hepatology
  25. Comparative analysis of vascular bulldog clamps used in laparoscopic liver resection.2021MedicineFree full text
  26. An Orthotopic Liver Transplantation Patient Survived Without Hepatic Artery Flow Due to Thrombosis: A Case Report.2021Transplantation proceedings
  27. Artificial intelligence for hepatitis evaluation.2021World journal of gastroenterologyFree full text
All its trials on ClinicalTrials.gov, any status12
  1. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  2. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)Active, not recruitingNCT05904886Study sitePhase 3Start 2023-09
  3. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  4. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  5. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Study sitePhase 3Start 2019-12
  6. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Study sitePhase 3Start 2019-12
  7. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  8. Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) SubjectsTerminatedNCT03591965Study sitePhase 2Start 2018-08
  9. Study of BGB-A317 in Participants With Previously Treated Unresectable HCCCompletedNCT03419897Study sitePhase 2Start 2018-04
  10. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)CompletedNCT03062358Study sitePhase 3Start 2017-04
  11. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  12. A Study to Evaluate SHR-1210 in Subjects With Advanced HCCCompletedNCT02989922Study sitePhase 2Start 2016-11

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 21 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
21
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 9920232024: 4420242025: 332025

4 hospitals in Hefei for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  2. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  3. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  4. Recruiting
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2021-06
    Registry
    NCT04900818

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopyImaging & AIImmunotherapy & targeted drugs
Departments in papersMedical oncologySurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyPathology / laboratory medicine
Papers it led21
  1. The simplified depth-predicting score outperforms the depth-predicting score for predicting the depth of invasion in differentiated early gastric cancer patients among nonexpert endoscopists.2025Gastroenterologia y hepatologia
  2. FPR3 sustains the immunosuppression of tumor-associated macrophages and accelerates the progression of gastric adenocarcinoma.2025Oncogene
  3. Increased keratin 80 expression predicts poor prognosis and promotes oxaliplatin resistance in gastric cancer.2025World journal of gastroenterologyFree full text
  4. Impacts and Pathways of Behavioral Activation on Psychological Distress Among Patients Diagnosed With Esophageal and Gastric Cancer in China: A Randomized Controlled Trial.2024Cancer medicineRCTFree full text
  5. KIRREL promotes the proliferation of gastric cancer cells and angiogenesis through the PI3K/AKT/mTOR pathway.2024Journal of cellular and molecular medicineFree full text
  6. Effect of Behavioral Activation on Stigma and Quality of Life in Patients With Advanced Esophageal and Gastric Cancer: A Randomized Controlled Trial.2024Psycho-oncologyRCT
  7. FTIR microspectroscopic study of gastric cancer AGS cells apoptosis induced by As2O3.2024Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  8. The Interaction Between SMAD1 and YAP1 Is Correlated with Increased Resistance of Gastric Cancer Cells to Cisplatin.2023Applied biochemistry and biotechnology
  9. Impact of low serum iron on treatment outcome of PD-1 inhibitors in advanced gastric cancer.2023BMC cancerFree full text
  10. The effect of short-term training about depth predicting score on the diagnostic ability of invasion depth for differentiated early gastric Cancer among non-expert endoscopists.2023BMC medical educationFree full text
  11. Development and Evaluation of a Novel Cuproptosis-Related lncRNA Signature for Gastric Cancer Prognosis.2023Computational and mathematical methods in medicineFree full text
  12. BASP1 expression is associated with poor prognosis and is correlated with immune infiltration in gastric cancer.2023FEBS open bioFree full text
  13. The value of contrast-enhanced harmonic endoscopic ultrasound in differential diagnosis and evaluation of malignant risk of gastrointestinal stromal tumors (<50mm).2023Scandinavian journal of gastroenterology
  14. Multi-omics characteristics of tumor-associated macrophages in the tumor microenvironment of gastric cancer and their exploration of immunotherapy potential.2023Scientific reportsFree full text
  15. Patients with brain metastases from gastric cancer.2023Tumori
  16. Novel prognostic indicator combining inflammatory indicators and tumor markers for gastric cancer.2023World journal of surgical oncologyFree full text
  17. Long non-coding RNA ZNF674-AS1 antagonizes oxaliplatin resistance of gastric cancer via regulating EZH2-mediated methylation of CHST7.2022AgingFree full text
  18. TWIST1-EP300 Expedites Gastric Cancer Cell Resistance to Apatinib by Activating the Expression of COL1A2.2022Analytical cellular pathology (Amsterdam)Free full text
  19. Comparison of diagnostic accuracy between linear EUS and miniprobe EUS for submucosal invasion in suspected cases of early gastric cancer.2022Revista espanola de enfermedades digestivas
  20. Prognostic Nomograms for Nonelderly Adults with Gastric Signet Ring Cell Carcinoma.2021BioMed research internationalFree full text
  21. Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancer.2021Investigational new drugs
Chinese-language papers (not in the count)1
  1. [Gastric-type extremely well-differentiated adenocarcinoma of the stomach with lymph node metastasis: report of a case].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status13
  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  2. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  3. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  4. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsRecruitingNCT04900818Study sitePhase 1Start 2021-06
  5. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Active, not recruitingNCT06356311Study sitePhase 3Start 2024-05
  6. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaTerminatedNCT06206278Study sitePhase 2Start 2023-10
  7. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerTerminatedNCT05149807Study sitePhase 2/Phase 3Start 2022-01
  8. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  9. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  10. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  11. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  12. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  13. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)TerminatedNCT03019588Study sitePhase 3Start 2017-02

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

3 hospitals in Hefei for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 6 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 4420242025: 112025

10 hospitals in Hefei for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Over half of these papers are lab or animal studies.

Papers it led6
  1. Circ_0079471 Regulates the Proliferation, Migration, Invasion and Apoptosis of Osteosarcoma Cells by Mediating miR-485-3p and TRIP6.2025Current medicinal chemistry
  2. Total femur replacement for juvenile primary osteosarcoma: A case report.2024Asian journal of surgery
  3. Single-Cell RNA Sequencing Pro-angiogenic Macrophage Profiles Reveal Novel Prognostic Biomarkers and Therapeutic Targets for Osteosarcoma.2024Biochemical genetics
  4. A Novel Defined Necroptosis-Related Genes Prognostic Signature for Predicting Prognosis and Treatment of Osteosarcoma.2024Biochemical genetics
  5. Identification of a pro-protein synthesis osteosarcoma subtype for predicting prognosis and treatment.2024Scientific reports
  6. Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies.2022BMC cancer
Earlier papers (2016–2020)7
  1. Increased expression of ecotropic viral integration site 2A indicates a poor prognosis and promotes osteosarcoma evolution through activating MEK/ERK pathway.2019Journal of receptor and signal transduction research
  2. The Roles of Circular RNAs in Osteosarcoma.2019Medical science monitor : international medical journal of experimental and clinical research
  3. LncRNA BLACAT1 accelerates the proliferation and migration of osteosarcoma cells through regulating STAT3.2019Pathology, research and practice
  4. Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.2018Investigational new drugs
  5. Osteosarcoma of the skull base: An analysis of 19 cases and literature review.2017Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  6. Cell Cycle Kinases in Osteosarcoma: Potential for Therapeutic Intervention.2016Current pharmaceutical design
  7. Co-delivery of doxorubicin and recombinant plasmid pHSP70-Plk1-shRNA by bacterial magnetosomes for osteosarcoma therapy.2016International journal of nanomedicine

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

3 hospitals in Hefei for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

6 hospitals in Hefei for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Hefei for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 7 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.4%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 3320242025: 222025

5 hospitals in Hefei for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskDrug combinations
Papers it led7
  1. Identification and construction of a novel NET-related gene signature for predicting prognosis in multiple myeloma.2025Clinical and experimental medicineFree full text
  2. CBX7 regulates chemotherapy-induced senescence-like growth arrest in multiple myeloma via the ERK/STAT3/PIM1 axis.2025Journal of translational medicineFree full text
  3. SRRM2 may be a potential biomarker and immunotherapy target for multiple myeloma: a real-world study based on flow cytometry detection.2024Clinical and experimental medicineFree full text
  4. Lipid levels and multiple myeloma risk: insights from Meta-analysis and mendelian randomization.2024Lipids in health and diseaseFree full text
  5. Identification of a novel lactylation-related gene signature predicts the prognosis of multiple myeloma and experiment verification.2024Scientific reportsFree full text
  6. Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at diagnosis in untreated multiple myeloma patients: a systematic review and meta-analysis.2023Clinical and experimental medicine
  7. Identification of biomarkers for early diagnosis of multiple myeloma by weighted gene co-expression network analysis and their clinical relevance.2022Hematology (Amsterdam, Netherlands)
All its trials on ClinicalTrials.gov, any status1
  1. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 4 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 1.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

4 hospitals in Hefei for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05667506

    Age 3 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChongqing, Guangzhou, Hefei, Nanchang, Nanjing, Tianjin, Wuhan, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesCAR-T & cell therapyChildrenMRD & relapse

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 1 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Hefei for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis & prognosisChildren

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 4 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 1.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 112025

6 hospitals in Hefei for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

3 hospitals in Hefei for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 2 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

2 hospitals in Hefei for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesBiologic drugsRelapse preventionAntibodies & diagnosis
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 4 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 222025

5 hospitals in Hefei for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Hefei for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status3
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  2. Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Study sitePhase 3Start 2020-12
  3. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Hefei for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

安徽医科大学第二附属医院

Second Affiliated Hospital of Anhui Medical University

合肥

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Second Hospital of Anhui Medical University; Second Hospital of Anhui Medical University (SHAMU); Second Hospital of Anhui Medical Hospital; Second Affiliated Hospital of Anhui Medical Univercity

Suggest a correctionDownload the data